KDR and non-small cell lung carcinoma: ,27,40, 41, 42 Consistent with our previous study in pretreated NSCLC,29 the addition of apatinib to camrelizumab decreased the incidence of RCCEP, suggesting the possible involvement of the VEGFA-VEGFR2 pathway in the pathogenesis of RCCEP.